Dr. Paul Friedlander

Chairman and Program Director

New Orleans LA UNITED STATES
1430 Tulane Avenue 2012
Otolaryngology

pfriedla@tulane.edu(504) 988-5454

Currently investigating head and neck cancer disparity and health equity

Social

Biography

Dr. Friedlander practicesat Tulane Medical Center, University Medical Center and the VA Medical Center (SLVHCS) . He received his B.S. in biology from Georgetown University and his M.D. from LSU (New Orleans). Following medical school, he completed a two-year General Surgery residency at George Washington University, an Otolaryngology residency at LSU (New Orleans), and a Head and Neck Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center. In 1997, he entered academic practice, where the majority of his effort was in translational research in head and neck cancers. He established a head and neck tumor bank, investigated and published on gene therapy using modified adenoviruses in targeting head and neck cancer as well as immunomodulation of head and neck cancer using the CD40 ligand protein. He joined Tulane in 2006 as an Associate Professor. He became the Chairman of the Department of Otolaryngology in 2009, the Residency Program Director in 2011, and currently serves in both roles. He established Healing Hands Across the Divide (2010) to address racial and socioeconomic head and neck cancer disparity. This has resulted in numerous publications and presentations. His current research focus is on head and neck cancer disparity and health equity.

Areas of Expertise

Mandible-Sparing Procedures for Oral Cavity Tumors

Circumferential Pharyngoesophageal Reconstruction

Salivary Gland Surgery

Parotid Surgery

Pharyngeal Surgery

Robotic-Assisted Surgery for Oral Cancer

Education

Memorial Sloan Kettering Cancer Center

Fellowship

Head and Neck Surgery

MD Anderson Cancer Center

Residency Rotation

Head and Neck Surgery

Louisiana University School of Medicine

Residency

Department of Otolaryngology-Head and Neck Surgery

Show All +

Media Appearances

More HPV vaccines could prevent head and neck cancers

Futurity: Research News

2018-05-22

“We want people to get vaccinated before they’re exposed to the virus,” Friedlander says. “Otolaryngologists should be actively engaged in promoting cancer vaccinations.”

Articles

Tumor necrosis factor-α triggers opposing signals in head and neck squamous cell carcinoma and induces apoptosis via mitochondrial- and non-mitochondrial-dependent pathways

International Journal of Oncology

Denis Selimović, Renate U Wahl, Emmanuelle Ruiz, Rizwan Aslam, Thomas W Flanagan, Sofie-Yasmin Hassan, Simeon Santourlidis, Youssef Haikel, Paul A Friedlander, Mosaad Megahed, Emad Kandil, Mohamed Hassan

2019

Head and neck squamous cell carcinoma (HNSCC) remains one of the most common malignancies worldwide. Although the treatment outcomes of HNSCC have improved in recent years, the prognosis of patients with advanced-stage disease remains poor. Current treatment strategies for HNSCC include surgery as a primary therapy, while radio-, chemo-, and biotherapeutics can be applied as second-line therapy.

Primary Squamous Cell Carcinoma of the Thyroid

Ochsner Journal

Blake Raggio Jeremy Barr Zahraa Ghandour Paul A Friedlander

2019

Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignancy of the head and neck, with fewer than 60 cases reported in the literature. We report a case of PSCCT and provide a brief review of the literature.

Improved Timeliness of Care for the Underserved: A Potential for Patient Navigation

Article

Jason F. Ohlstein, Thomas S Edwards, Charles Riley, Joseph F Buell, Paul A Friedlander

2019

Minorities suffer disproportionately worse outcomes in malignancies of the head and neck; Here we seek to determine the potential for patient navigation to improve the timeliness of head and neck cancer care in an underserved population.